Sage Therapeutics and partner Biogen equally share profits and losses for the commercialization of Zurzuvae in the United States. In ex-U.S. markets, Biogen records product sales (excluding Japan ...

SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.

Achieved $13.8 million in ZURZUVAE® (zuranolone) collaboration revenue in the first quarter of 2025 (50% of the net revenues recorded by Biogen ... remains ongoing Sage Therapeutics, Inc ...

April 29, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq ... revenue represents 50% of the net revenue recorded when Biogen ships ZURZUVAE to the distributors. In terms of prescriber ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (SAGE), today reported ... Collaboration revenue represents 50% of the net revenue recorded when Biogen ships ZURZUVAE to the distributors.

Welcome to Sage Therapeutics First Quarter 2025 Financial ... which represents 50% of the net revenue recorded by Biogen, a 21% increase from the fourth quarter of 2024. Importantly, we are ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

Sage Therapeutics, Inc. SAGE reported a loss of $1.01 per share for the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 99 cents. The company had reported a loss of $1. ...

Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025.